Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia.
Stephen R MarderHans ErikssonYudong ZhaoMary HobartPublished in: Acta neuropsychiatrica (2020)
Pre-specified sensitivity analyses showed separation from placebo for brexpiprazole at Week 6. A post hoc analysis suggested a potential confounding of efficacy rating towards symptom improvement in patients who experience known side effects of quetiapine XR.
Keyphrases
- placebo controlled
- double blind
- major depressive disorder
- phase iii
- study protocol
- bipolar disorder
- phase ii
- clinical trial
- phase ii study
- liver failure
- respiratory failure
- randomized controlled trial
- open label
- drug induced
- intensive care unit
- squamous cell carcinoma
- patient reported
- liquid chromatography
- risk assessment
- hepatitis b virus
- extracorporeal membrane oxygenation